VIP as a Potential Therapeutic Agent in Gram Negative Sepsis

Author(s): Hiba Ibrahim, Paul Barrow, Neil Foster

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 12 , Issue 4 , 2012


Become EABM
Become Reviewer
Call for Editor

Abstract:

Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.

Keywords: Cytokine, inflammation, Sepsis, transcription bacteria, VIP, Systemic inflammatory response syndrome (SIRS), pathogen-associated molecular patterns (PAMPs), Toll-like receptor (TLR), cardiovascular collapse, dysregulated cytokine production, Pathogen Recognition, Therapeutic targets.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 4
Year: 2012
Published on: 31 October, 2012
Page: [308 - 315]
Pages: 8
DOI: 10.2174/187153012803832611
Price: $65

Article Metrics

PDF: 14